CRLBFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Cresco Labs Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 6, 2026
$0.58−0.02 (-3.13%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.6441 (−52.80%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Cresco Labs Inc. saw revenue fall 9.5% to $655.85M over fiscal 2025. Operating income fell 126.1% to -$27.99M, moving the operating margin from 14.8% to -4.3%. Free cash flow was $37.75M, down 66.6% from a year earlier.
Revenue
$655.85M
-9.5% vs. a year earlier
Operating income
-$27.99M
-126.1% vs. a year earlier
Free cash flow
$37.75M
-66.6% vs. a year earlier
EPS, diluted
-$0.38
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $655.85M
- Net income
- -$135.41M
- EPS, diluted
- -$0.38
- Free cash flow
- $37.75M
Seven years at a glance
Fiscal years 2019 to 2025, USD
Revenue
$655.85M-9.5% YoY
Gross profit
$324.57M-10.9% YoY
Operating income
-$27.99M-126.1% YoY
Net income
-$135.41M
EPS, diluted
-$0.38
Free cash flow
$37.75M-66.6% YoY
Reported period